Affiliation:
1. Harvard Medical School, Boston, Massachusetts
2. Fenway Community Health, Boston, Massachusetts
3. Brown University School of Medicine, Providence, Rhode Island
Abstract
ABSTRACT
Community-acquired methicillin-resistant
Staphylococcus aureus
(MRSA) skin and soft tissue infections (SSTI) have become increasingly common. This study's objectives were to describe the clinical spectrum of MRSA in a community health center and to determine whether the use of specific antimicrobials correlated with increased probability of clinical resolution of SSTI. A retrospective chart review of 399 sequential cases of culture-confirmed
S. aureus
SSTI, including 227 cases of MRSA SSTI, among outpatients at Fenway Community Health (Boston, MA) from 1998 to 2005 was done. The proportion of
S. aureus
SSTI due to MRSA increased significantly from 1998 to 2005 (
P
< 0.0001). Resistance to clindamycin was common (48.2% of isolates). At the beginning of the study period, most patients with MRSA SSTI empirically treated with antibiotics received a beta-lactam, whereas by 2005, 76% received trimethoprim-sulfamethoxazole (TMP-SMX) (
P
< 0.0001). Initially, few MRSA isolates were sensitive to the empirical antibiotic, but 77% were susceptible by 2005 (
P
< 0.0001). A significantly higher percentage of patients with MRSA isolates had clinical resolution on the empirical antibiotic by 2005 (
P
= 0.037). Use of an empirical antibiotic to which the clinical isolate was sensitive was associated with increased odds of clinical resolution on empirical therapy (odds ratio = 5.91), controlling for incision and drainage and HIV status. MRSA now accounts for the majority of SSTI due to
S. aureus
at Fenway, and improved rates of clinical resolution on empirical antibiotic therapy have paralleled increasing use of empirical TMP-SMX for these infections. TMP-SMX appears to be an appropriate empirical antibiotic for suspected MRSA SSTI, especially where clindamycin resistance is common.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Reference24 articles.
1. Centers for Disease Control and Prevention. 2003. Outbreaks of community-associated methicillin-resistant Staphylococcus aureus skin infections—Los Angeles County, California, 2002-2003. Morb. Mortal. Wkly. Rep.52:88.
2. Crum, N. F. 2005. The emergence of severe, community-acquired methicillin-resistant Staphylococcus aureus infections. Scand. J. Infect. Dis.37:651-656.
3. Ellis, M. W., and J. S. Lewis II. 2005. Treatment approaches for community-acquired methicillin-resistant Staphylococcus aureus infections. Curr. Opin. Infect. Dis.18:496-501.
4. Methicillin-ResistantStaphylococcus aureusDisease in Three Communities
5. Gorwitz R. J. D. B. Jernigan J. H. Powers J. A. Jernigan and Participants in the CDC-Convened Experts' Meeting on Management of MRSA in the Community. 2006. Strategies for clinical management of MRSA in the community: summary of an experts' meeting convened by the Centers for Disease Control and Prevention. [Online.] http://www.cdc.gov/ncidod/dhqp/pdf/ar/CAMRSA_ExpMtgStrategies.pdf
. Accessed 14 December 2006.
Cited by
114 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献